EyePoint Pharmaceuticals, Inc. — Director's Dealing 2021

Mar 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2021-02-28

Reporting Person: Jones David Scott (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-28	Common Stock	M	4105.00	$0.00	Acquired	9082.00	Direct
2021-02-28	Common Stock	F	1702.00	$10.81	Disposed	7380.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-28	Restricted Stock Units	$0.00	M	4105.00	Disposed		Common Stock (4105.00)	Direct

Footnotes

F1: Includes 1,308 shares acquired on July 31, 2020 and 970 shares acquired on January 29, 2021 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.

F2: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units

F3: The restricted stock units will vest in three equal installments on the following dates: 6.30.2020, 2.28.2021 and 2.28.2022.